Clinical Trial

A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is a multicenter, randomized, open-label, parallel-controlled, phase III study to compare the efficacy, safety, and tolerability of HRS9531 versus semaglutide once weekly (QW) in adult subjects with obesity
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-12-03; most recent amendment 2026-02-26.
Status change: Recruiting → Active, Not Recruiting 2026-02-26
Status change: Not Yet Recruiting → Recruiting 2025-12-29
Trial Details
NCT Number NCT07285902
Lead Sponsor Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions Obesity
Enrollment 572 participants
Start Date 2025-12-25
Primary Completion 2027-03 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-02-27